A suggested 15% tetrahydrocannabinol (THC) potency cap for cannabis products in Vermont’s adult-use cannabis market has been dismissed after a strong debate among the Vermont legislature.
The state’s leading physician advocacy group, the Vermont Medical Society, initially issued the rejected recommendations to the Cannabis Control Board. However, following much deliberation, board members decided that the current 30% statutory cap on THC concentration in cannabis flower is appropriate.
According to members of the Vermont Medical Society, THC—the primary psychotropic cannabinoid found in cannabis—may impair a person’s ability to drive, harm fetuses, cause addiction, and contribute to psychotic disorders. However, many of these myths have already been dispelled.
In addition to its failed attempt to lower the cannabis potency cap in Vermont, the Vermont Medical Society also wanted to ban any products containing more than 15% THC. “Marijuana use is a significant public health problem in Vermont, and it is getting worse,” argued the state’s health department, which fears that THC may pose more of a risk than a benefit for individuals who do not consume the plant as frequently as others.
Vermont has already introduced a potency cap for its looming recreational cannabis legalization market, with flower capped at 30% and THC and concentrates capped at 60%. Interestingly, medical cannabis products in Vermont are not restricted based on their level of cannabinoid potency. At the current time, Vermont is the only U.S. state to impose THC potency limits.
The rules won’t be effectuated until they are filed with the secretary of state’s office, at which point they will need to be publicly commented on and reviewed by the legislature so as to ensure that they remain consistent with the state’s adult-use cannabis law.
Adult-use cannabis was officially legalized in Vermont in 2018 with the passing of House Bill 511, a revised version of an earlier bill. Medical cannabis was legalized 14 years prior in 2004. However, qualifying patients were forced to wait until 2013 to access the state’s licensed dispensaries for their medicine.
The law evolved to become what is now known as Act 86. This legislation permits cannabis possession up to 1 ounce, in addition to two mature and four immature cannabis plants for adults aged 21 and above. Public cannabis consumption is prohibited, as well as the use of the plant in spaces where tobacco smoking is forbidden.
Retail cannabis stores are set to open their doors in the spring of 2022. For the time being, only registered medical cannabis patients can access legal cannabis. When the eagerly anticipated moment happens, consumers can expect the following:
News of the Cannabis Control Board’s refusal to lower THC potency limits comes after Vermont Democratic and Progressive lawmakers submitted a new bill to decriminalize drug possession. Should the harm reduction policy be approved, it stands to help manage and reduce racial disparities in enforcement.
Introduced by Reps. Logan Nicoll and Selene Colburn, the legislation would make the distribution and possession of personal-use amounts of illegal substances punishable by a $50 fine without the risk of jail time. Since July 1, 2018, adults aged 21 and older have been legally allowed to possess 1 ounce of cannabis, two mature plants, four immature plants, and 5 grams of hashish.
Projections featured in the 2021 MJBizFactbook suggest that Vermont’s adult-use cannabis program could be generating $145 million in revenue by its fourth year of operation.
It’s safe to say that the wheels on the cannabis reform express have certainly been set in motion. As of April 2022, 47 states have legalized cannabis in some form or another. However, the plant’s federally illegal status—U.S. law categorizes cannabis as a Schedule I drug—means that businesses operating in this industry cannot conduct transactions with…
Cannabis’ former reputation as a gateway drug may have been dispelled, but it turns out that there is some element of truth to the rumor: The plant’s progressively evolving status as a normalized medicine in 37 U.S. states and a recreational substance in 18 U.S. states is prompting a wave of change across America’s statehouses….
Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa. Nicknamed “K,” “special K,” “cat valium,” and “vitamin K,” ketamine is…
Austin decriminalized cannabis possession, Vancouver is now home to some not-so-legal magic mushroom shops, and a British woman shared her life-changing medical marijuana journey. Let’s dive into this week’s cannanews. Austin Voters Pass Cannabis Decriminalization Bill Voters in Austin, Texas, have approved Proposition A, a ballot measure that decriminalizes cannabis possession and bans no-knock warrants….
Have you ever wondered whether one can be allergic to cannabis? Some may laugh at the suggestion of one being allergic to cannabis considering its widely known safety and efficacy. However, like most substances, there may be some individuals who are allergic to it. According to the Asthma and Allergy Foundation of America, more than…
The worldwide skincare industry, which is projected to inflate to $189.3 billion USD by 2025, could soon be merging more closely with…
There’s no denying the fact that CBD is dominating the wellness landscape. Increasing awareness of the cannabinoid’s medicinal effects is going hand-in-hand…